➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Dow
Express Scripts
McKinsey
Merck
McKesson

Last Updated: June 5, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for VX-661


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug VX-661?

VX-661 is an investigational drug.

There have been 34 clinical trials for VX-661. The most recent clinical trial was a Phase 3 trial, which was initiated on May 1st 2015.

The most common disease conditions in clinical trials are Cystic Fibrosis, Fibrosis, and [disabled in preview]. The leading clinical trial sponsors are Vertex Pharmaceuticals Incorporated and [disabled in preview].

There are sixty-five US patents protecting this investigational drug and six hundred and ninety-one international patents.

Recent Clinical Trials for VX-661
TitleSponsorPhase
A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis and F/MF GenotypesVertex Pharmaceuticals IncorporatedPhase 3
A Study Evaluating the Long-Term Safety of Elexacaftor Combination TherapyVertex Pharmaceuticals IncorporatedPhase 3
Evaluation of Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are 6 Years of Age and OlderVertex Pharmaceuticals IncorporatedPhase 3

See all VX-661 clinical trials

Clinical Trial Summary for VX-661

Top disease conditions for VX-661
Top clinical trial sponsors for VX-661

See all VX-661 clinical trials

US Patents for VX-661

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
VX-661   Start Trial Compounds, compositions, and methods for increasing CFTR activity Proteostasis Therapeutics, Inc. (Boston, MA)   Start Trial
VX-661   Start Trial Modulators of ATP-binding cassette transporters Vertex Pharmaceuticals Incorporated (Boston, MA)   Start Trial
VX-661   Start Trial Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxo1-5-y1)-N-(1-(2,3-dihydroxypropy1)-6- -fluoro-2-(1-hydroxy-2-methylpropan-2-y1)-1H-indol-5-y1) cyclopropanecarbox-amide and administration thereof Vertex Pharmaceuticals Incorporated (Boston, MA)   Start Trial
VX-661   Start Trial Process of producing cycloalkylcarboxamido-indole compounds Vertex Pharmaceuticals Incorporated (Boston, MA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for VX-661

Drugname Country Document Number Estimated Expiration Related US Patent
VX-661 Australia 2015229117 2034-03-13   Start Trial
VX-661 Canada 2942387 2034-03-13   Start Trial
VX-661 European Patent Office 3116870 2034-03-13   Start Trial
VX-661 World Intellectual Property Organization (WIPO) 2015138934 2034-03-13   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
Mallinckrodt
McKesson
Harvard Business School
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.